The Board of Boule Diagnostics AB has decided to withdraw the previously communicated dividend proposal of SEK 0.60 per share, a total of SEK 11.6 million. The Board proposes instead that no dividend will be paid.
The Board’s decision was made in light of the increased uncertainty of the market outlook following the global spread of the Coronavirus. To date, the Coronavirus have caused no significant negative effect on Boule. The Group has a solid financial position with an, per year-end 2019, equity/assets ratio of 57 percent and available cash and cash equivalents of SEK 78.6 million.
The Board’s decision does not affect the long-term dividend policy. The proposed exception from the policy is a precautionary measure to secure Boule’s financial position should one or more of Boule’s key markets become the subject of prolonged lockdowns like those we are currently seeing in India, Europe and parts of the US.
For further information, please contact:
Peter Ehrenheim, Chairman of the Board, Boule Diagnostics AB, phone +46 (0)706-67 57 11
Christina Rubenhag, Acting CEO and CFO, Boule Diagnostics AB, phone +46 (0)705-46 72 22
About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.com
The information was submitted for publication, through the agency of the contact person set out above at 10:10 CET on April 2, 2020.